Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NEWS-
Deity’s Improved eCommerce Site Now Online; New Product Offering to Soon Follow
KATY, TX / ACCESSWIRE / April 8, 2022 / Neutra Corp. (OTC PINK:NTRR) announced that it has launched subsidiary Deity Wellness' revamped ecommerce platform, completing a project designed to make the site more SEO-focused and user friendly. The company also said Deity has a new product in development that it hopes will hit the market in coming weeks.
"We always want to be innovative and bring the best value to our customers," said Neutra CEO Sydney Jim. "To that end, we've been busy making some big changes. The just-completed ecommerce platform, for example, moves us forward in many positive ways, greatly increasing our online presence. Deity has also redesigned its packaging to better position us in customers' minds. Finally, we have a new product offering that we want to launch in April 2022 that should make a big splash in the market. There's a lot to like as we continuously push ourselves to grow."
Deity's ecommerce platform should be much easier for potential customers to find, thanks to its enhanced SEO. Buying Deity products from the site is now much more fluid and automated, which will lead to a better customer experience. Neutra's web team will now turn its attention of the VIVIS ecommerce site.
Meanwhile, Deity has also redesigned the packaging for its 10-pack of 25-mg Delta-8 gummies and vape cartridges. The new designs reflect the brand's maturity and staying power in the increasingly popular alternative cannabinoid market. This will also serve as a key differentiator between Deity products and those of the competition.
Deity is working on the debut of a new product the company hopes to have available on its revamped ecommerce platform and on store shelves by the end of April 2022.
About Neutra Corp.
thats 50 stores nation wide$$$$
they have 50 st0res already with delta-8, $$$$$$$
NTRR-
GORDON vestal jr
@GORDONvestaljr2
·
Apr 1
Replying to
@CorpNeutra
can u sale delta-8 to these stores,if u can,r u going to do it,thank u in advance for ur reply
Neutra Corp
@CorpNeutra
·
15h
We are already in about 50 stores nationwide
ntrr-tweed
GORDON vestal jr
@GORDONvestaljr2
·
Apr 1
Replying to
@CorpNeutra
can u sale delta-8 to these stores,if u can,r u going to do it,thank u in advance for ur reply
Neutra Corp
@CorpNeutra
·
15h
We are already in about 50 stores nationwide
-
NTRR-TWEED-
GORDON vestal jr
@GORDONvestaljr2
·
Apr 1
Replying to
@CorpNeutra
can u sale delta-8 to these stores,if u can,r u going to do it,thank u in advance for ur reply
Neutra Corp
@CorpNeutra
·
15h
We are already in about 50 stores nationwide
GORDON vestal jr
@GORDONvestaljr2
·
Apr 1
can u sale delta-8 to these stores,if u can,r u going to do it,thank u in advance for ur reply
Neutra Corp
@CorpNeutra
Replying to
@GORDONvestaljr2
We are already in about 50 stores nationwide
11:03 PM · Apr 6, 2022·Twitter Web App
GORDON vestal jr
@GORDONvestaljr2
·
Apr 1
can u sale delta-8 to these stores,if u can,r u going to do it,thank u in advance for ur reply
Neutra Corp
@CorpNeutra
Replying to
@GORDONvestaljr2
We are already in about 50 stores nationwide
11:03 PM · Apr 6, 2022·Twitter Web App
See new Tweets
Conversation
Neutra Corp
@CorpNeutra
$NTRR Deity Wellness brand new e-commerce platform finishing final touches and should launch this week!!!
12:22 PM · Mar 28, 2022·Twitter for iPhone
.0014x.0015
Post#
19434
of 19447
I had a really good/long talk with Sidney last night and got a lot of things cleared up.
There's going to be some great news coming very soon!!
He also still claims there hasn't been ANY selling from him or his team in relation to the stock.
He's well aware of the manipulation at this time, but isn't concerned enough to pay for investigation of the sellers.
I don't want to spoil any upcoming pr, but several things have also been put in place to assist in clearing of the debt.
Among several other exciting updates. :D
Take on the markets w/ confidence. E*TRADE's easy to use tools help make
KABOOM,KABOOM,MONEY HERE SOON,$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$4
thanks rip for update
hello
yes,yes,YES.bring it on,lets boogie,$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
Neutra's VIVIS Excited to Release New Gummy!
KATY, TX / ACCESSWIRE / January 18, 2022 / Neutra Corp. (OTC PINK:NTRR) continues plans for Phase-1 clinical trials regarding the effectiveness of two hemp-based cannabinoids (CBDa) in stopping COVID-19 infection. The tests seek to build upon an earlier Oregon State University study published in the Journal of Nature Products that showed cannabis compounds cannabidiolic acid (CBDa) and cannabigerolic acid (CBGa) prevented the coronavirus from penetrating human cells. Bloomberg recently reported on the study and its results.
"We remain committed to these hemp-based CBD phase-1 clinical trials," said Neutra CEO Sydney Jim. "The earlier study showed great promise. I know it will take time to get started and but this is part of our plans for 2022. We are hopeful that our trials will show that hemp-based cannabinoid compounds to be a safe way to help to protect people from the coronavirus and SARS-CoV-2 that continues to plague the world after two years."
Neutra announced last September that its VIVIS subsidiary had signed a letter of intent with Mercury Clinical Research to pursue such trials. The main uses for CBD have been helping with inflammation, anxiety and sleep. The trials could also investigate additional hemp-based compound uses for anti-inflammation, anti-insomnia, appetite suppressant and stimulant (CBG vs. CBN), recovery, pain-management, anti-anxiety, and other health related diagnosis
CBDa and CBGa can be taken orally. Based on the published Oregon State study, VIVIS has developed a new gummy product containing the compounds. The company expects the gummy to help in the battle against COVID. CBDa can be used to combat inflammation, pain and nausea. CBGa may also be effective in fighting metabolic disorders and cardiovascular disease.
About Neutra Corp.
Neutra Corp. (OTC PINK:NTRR) is an early-stage research and development company with a focus on bringing modern healthy living solutions to a multibillion-dollar market. Cutting-edge technologies within the nutraceuticals, food, and drug, and environmental purification sectors are creating a new kind of world culture-one where in which consumers are demanding access to products that promote health and stave off potential health dangers. One of the nutraceutical sub-markets is the new thriving hemp-based CBD market, in which the Company intends to participate. For more information, visit the Company's website at http://www.NeutraInc.com.
NOTICE REGARDING FORWARD-LOOKING STATEMENTS
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words 'believes,' 'expects,' 'anticipate' or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.
Neutra Contact:
Neutra's VIVIS Excited to Release New Gummy!
KATY, TX / ACCESSWIRE / January 18, 2022 / Neutra Corp. (OTC PINK:NTRR) continues plans for Phase-1 clinical trials regarding the effectiveness of two hemp-based cannabinoids (CBDa) in stopping COVID-19 infection. The tests seek to build upon an earlier Oregon State University study published in the Journal of Nature Products that showed cannabis compounds cannabidiolic acid (CBDa) and cannabigerolic acid (CBGa) prevented the coronavirus from penetrating human cells. Bloomberg recently reported on the study and its results.
"We remain committed to these hemp-based CBD phase-1 clinical trials," said Neutra CEO Sydney Jim. "The earlier study showed great promise. I know it will take time to get started and but this is part of our plans for 2022. We are hopeful that our trials will show that hemp-based cannabinoid compounds to be a safe way to help to protect people from the coronavirus and SARS-CoV-2 that continues to plague the world after two years."
Neutra announced last September that its VIVIS subsidiary had signed a letter of intent with Mercury Clinical Research to pursue such trials. The main uses for CBD have been helping with inflammation, anxiety and sleep. The trials could also investigate additional hemp-based compound uses for anti-inflammation, anti-insomnia, appetite suppressant and stimulant (CBG vs. CBN), recovery, pain-management, anti-anxiety, and other health related diagnosis
CBDa and CBGa can be taken orally. Based on the published Oregon State study, VIVIS has developed a new gummy product containing the compounds. The company expects the gummy to help in the battle against COVID. CBDa can be used to combat inflammation, pain and nausea. CBGa may also be effective in fighting metabolic disorders and cardiovascular disease.
About Neutra Corp.
Neutra Corp. (OTC PINK:NTRR) is an early-stage research and development company with a focus on bringing modern healthy living solutions to a multibillion-dollar market. Cutting-edge technologies within the nutraceuticals, food, and drug, and environmental purification sectors are creating a new kind of world culture-one where in which consumers are demanding access to products that promote health and stave off potential health dangers. One of the nutraceutical sub-markets is the new thriving hemp-based CBD market, in which the Company intends to participate. For more information, visit the Company's website at http://www.NeutraInc.com.
NOTICE REGARDING FORWARD-LOOKING STATEMENTS
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words 'believes,' 'expects,' 'anticipate' or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.
Neutra Contact:
Neutra's VIVIS Excited to Release New Gummy!
KATY, TX / ACCESSWIRE / January 18, 2022 / Neutra Corp. (OTC PINK:NTRR) continues plans for Phase-1 clinical trials regarding the effectiveness of two hemp-based cannabinoids (CBDa) in stopping COVID-19 infection. The tests seek to build upon an earlier Oregon State University study published in the Journal of Nature Products that showed cannabis compounds cannabidiolic acid (CBDa) and cannabigerolic acid (CBGa) prevented the coronavirus from penetrating human cells. Bloomberg recently reported on the study and its results.
"We remain committed to these hemp-based CBD phase-1 clinical trials," said Neutra CEO Sydney Jim. "The earlier study showed great promise. I know it will take time to get started and but this is part of our plans for 2022. We are hopeful that our trials will show that hemp-based cannabinoid compounds to be a safe way to help to protect people from the coronavirus and SARS-CoV-2 that continues to plague the world after two years."
Neutra announced last September that its VIVIS subsidiary had signed a letter of intent with Mercury Clinical Research to pursue such trials. The main uses for CBD have been helping with inflammation, anxiety and sleep. The trials could also investigate additional hemp-based compound uses for anti-inflammation, anti-insomnia, appetite suppressant and stimulant (CBG vs. CBN), recovery, pain-management, anti-anxiety, and other health related diagnosis
CBDa and CBGa can be taken orally. Based on the published Oregon State study, VIVIS has developed a new gummy product containing the compounds. The company expects the gummy to help in the battle against COVID. CBDa can be used to combat inflammation, pain and nausea. CBGa may also be effective in fighting metabolic disorders and cardiovascular disease.
About Neutra Corp.
Neutra Corp. (OTC PINK:NTRR) is an early-stage research and development company with a focus on bringing modern healthy living solutions to a multibillion-dollar market. Cutting-edge technologies within the nutraceuticals, food, and drug, and environmental purification sectors are creating a new kind of world culture-one where in which consumers are demanding access to products that promote health and stave off potential health dangers. One of the nutraceutical sub-markets is the new thriving hemp-based CBD market, in which the Company intends to participate. For more information, visit the Company's website at http://www.NeutraInc.com.
NOTICE REGARDING FORWARD-LOOKING STATEMENTS
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words 'believes,' 'expects,' 'anticipate' or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.
Neutra Contact:
Neutra's VIVIS Excited to Release New Gummy!
KATY, TX / ACCESSWIRE / January 18, 2022 / Neutra Corp. (OTC PINK:NTRR) continues plans for Phase-1 clinical trials regarding the effectiveness of two hemp-based cannabinoids (CBDa) in stopping COVID-19 infection. The tests seek to build upon an earlier Oregon State University study published in the Journal of Nature Products that showed cannabis compounds cannabidiolic acid (CBDa) and cannabigerolic acid (CBGa) prevented the coronavirus from penetrating human cells. Bloomberg recently reported on the study and its results.
"We remain committed to these hemp-based CBD phase-1 clinical trials," said Neutra CEO Sydney Jim. "The earlier study showed great promise. I know it will take time to get started and but this is part of our plans for 2022. We are hopeful that our trials will show that hemp-based cannabinoid compounds to be a safe way to help to protect people from the coronavirus and SARS-CoV-2 that continues to plague the world after two years."
Neutra announced last September that its VIVIS subsidiary had signed a letter of intent with Mercury Clinical Research to pursue such trials. The main uses for CBD have been helping with inflammation, anxiety and sleep. The trials could also investigate additional hemp-based compound uses for anti-inflammation, anti-insomnia, appetite suppressant and stimulant (CBG vs. CBN), recovery, pain-management, anti-anxiety, and other health related diagnosis
CBDa and CBGa can be taken orally. Based on the published Oregon State study, VIVIS has developed a new gummy product containing the compounds. The company expects the gummy to help in the battle against COVID. CBDa can be used to combat inflammation, pain and nausea. CBGa may also be effective in fighting metabolic disorders and cardiovascular disease.
About Neutra Corp.
Neutra Corp. (OTC PINK:NTRR) is an early-stage research and development company with a focus on bringing modern healthy living solutions to a multibillion-dollar market. Cutting-edge technologies within the nutraceuticals, food, and drug, and environmental purification sectors are creating a new kind of world culture-one where in which consumers are demanding access to products that promote health and stave off potential health dangers. One of the nutraceutical sub-markets is the new thriving hemp-based CBD market, in which the Company intends to participate. For more information, visit the Company's website at http://www.NeutraInc.com.
NOTICE REGARDING FORWARD-LOOKING STATEMENTS
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words 'believes,' 'expects,' 'anticipate' or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.
Neutra Contact:
bye,bye,i am out of here
sorry i mean 1for200
u r so right200for1 will wipe u out and then on top of that,he going to up the as to 20billion,its hard to even think hes going to do this what a skum bag he is
right after i posted the good news on this stock today
sgmd,do not buy this stock just had a r/s 1 for 200
Sugarmade Signs Binding LOI to Enter Rare Cannabinoid Market via License Agreement for Patented THC-V Rich Chemovars
Sugarmade, Inc.
Mon, January 24, 2022, 8:30 AM
NEW YORK, Jan. 24, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – Sugarmade, Inc. (OTC Pink: SGMD) ("Sugarmade", "SGMD" or the "Company") an emerging leader in the licensed cannabis sector, is pleased to announce the signing of a binding Letter of Intent (the “LOI”) with GenCann, Inc. (“GenCann”), the exclusive licensor for a set of cannabis chemovars particularly rich in the cannabinoid Tetrahydrocannabivarin (THC-V) (the “GenCann Chemovars”).
Under the terms outlined in the LOI, Sugarmade and its licensed cannabis cultivator partners will be granted a 5-year license to cultivate what the Company believes to be some of the highest THC-V-containing strains in existence. Sugarmade and GenCann plan to begin clone production immediately upon the signing of the final agreement with a cultivation program beginning in Lake County, California, this spring.
“While THC-V is sometimes referred to as a ‘rare cannabinoid,’ we believe the term no longer applies relative to our planned cultivation effort using GenCann’s Chemovars,” commented Jimmy Chan, CEO of Sugarmade. “The test results from certified California laboratories of these chemovars are certainly impressive, with THC-V yields in flower of up to 8%. We think the GenCann Chemovars are a game-changer in the cannabinoid space. Sugarmade plans to make a substantial commitment to bring products based on THC-V to the California market and perhaps to other states in the future. Stay tuned for our upcoming product plan announcements.”
The GenCann Chemovars are covered by multiple issued U.S. patents, including patent numbers PP33212 for the plant called “V1,” patent number PP33211 for the plant called “V2” and patent number PP33210 for the plant called “V3.” All three of these chemovars contain abundant THC-V, with the V1 variety being especially distinguished by producing more THC-V than THC by percent weight. The V3 strain, also known as Skelator, will be the predominant strain utilized for spring cultivation due to its early finishing characteristics and its higher THC-V content, although the V1 and V2 varieties are also planned for Sugarmade’s cultivation effort.
Sugarmade plans to utilize the THC-V rich biomass in a series of products it plans to introduce to the licensed California marketplace. The first of these will be THC-V-rich smokeable flower and THC-V-rich gummy candies. In the future, Sugarmade plans to also produce distillate and isolate products based on its cultivated biomass.
Chan continued, “The THC-V smoking and edibles consumption experience is very different compared to traditional cannabis. Where legacy cannabis strains often produce a sedating effect, consumption of THC-V rich products produces a pleasant and uplifting effect. It’s a remarkable experience and we believe consumers will gravitate to it.”
In addition to seeking to supply the mainstream cannabis marketplace with THC-V products, Sugarmade also plans to seek pharmaceutical and nutraceutical partners for supply agreements as many of these companies are already stating their intentions to conduct trials or to produce products containing rare cannabinoids.
The cultivated THC-V cannabinoids from the GenCann Chemovars differ significantly from the current generation of THC-V products presently available in the marketplace, most of which are converted via a chemical process from hemp-based isolates. This generation of products is also very expensive, often priced in the $50 per gram range, and is typically not tested by certified laboratories. Additionally, the cannabinoids produced by the GenCann Chemovars differ from planned offerings by other companies that utilize genetically modified organisms, such as bacteria or yeast, to create cannabinoids outside of the cannabis plant varieties. All of the cannabinoids to be generated via the GenCann Chemovars and Sugarmade’s cultivation will be produced from real cannabis plants that have been specifically bred for this purpose and grown in an outdoor setting.
Sugarmade and GenCann believe outdoor cultivation of THC-V-rich strains will yield higher desirable cannabinoid content due to optimal ultraviolet light levels inherent in natural sunlight.
About THC-V
THC is found in the form of Tetrahydrocannabinolic acid (THCA) that is converted to THC during drying or under high heat. Similarly, THC-V in live plants is in the form of tetrahydrocannabivarin carboxylic acid (THCVA). THC and THC-V both bind to the cannabinoid receptors 1 (CB1) and 2 (CB2) although the exact effects of binding are not fully understood. Binding of CB1 by its endogenous ligands, anandamide or 2-arachidonoylglycerol, stimulates food intake (Silvestri, C., Di Marzo, V. 17 Cell Metabolism 475-490 (2013)). THC acts as an agonist of CB1 and stimulates appetite. THC-V has been shown to be a mild antagonist of CB1 and lessens sensations of hunger (Pertwee, R G. 153 British Journal of Pharmacology 199-215 (2008)). The ability of THC-V to act as an antagonist of CB1 has led to investigation of using THC-V to treat metabolic syndrome and obesity (Riedel, G., et al., 156 British Journal of Pharmacology 1154-1166 (2009)). Selection of a variety producing increased amounts of THC-V allows optimized isolation of THC-V which may be used in the treatment of metabolic syndrome.
About Sugarmade
Sugarmade, Inc. (OTC Pink: SGMD) is a product and branding marketing company investing in operations and technologies with disruptive potential. Our Brand portfolio includes CarryOutsupplies.com, SugarRush™, NUG Avenue, Lemon Glow and Budcars. Sugarmade is also the first licensee of the unique and patented Gen
sgmd-Sugarmade Signs Binding LOI to Enter Rare Cannabinoid Market via License Agreement for Patented THC-V Rich Chemovars
Sugarmade, Inc.
Mon, January 24, 2022, 8:30 AM
NEW YORK, Jan. 24, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – Sugarmade, Inc. (OTC Pink: SGMD) ("Sugarmade", "SGMD" or the "Company") an emerging leader in the licensed cannabis sector, is pleased to announce the signing of a binding Letter of Intent (the “LOI”) with GenCann, Inc. (“GenCann”), the exclusive licensor for a set of cannabis chemovars particularly rich in the cannabinoid Tetrahydrocannabivarin (THC-V) (the “GenCann Chemovars”).
Under the terms outlined in the LOI, Sugarmade and its licensed cannabis cultivator partners will be granted a 5-year license to cultivate what the Company believes to be some of the highest THC-V-containing strains in existence. Sugarmade and GenCann plan to begin clone production immediately upon the signing of the final agreement with a cultivation program beginning in Lake County, California, this spring.
“While THC-V is sometimes referred to as a ‘rare cannabinoid,’ we believe the term no longer applies relative to our planned cultivation effort using GenCann’s Chemovars,” commented Jimmy Chan, CEO of Sugarmade. “The test results from certified California laboratories of these chemovars are certainly impressive, with THC-V yields in flower of up to 8%. We think the GenCann Chemovars are a game-changer in the cannabinoid space. Sugarmade plans to make a substantial commitment to bring products based on THC-V to the California market and perhaps to other states in the future. Stay tuned for our upcoming product plan announcements.”
The GenCann Chemovars are covered by multiple issued U.S. patents, including patent numbers PP33212 for the plant called “V1,” patent number PP33211 for the plant called “V2” and patent number PP33210 for the plant called “V3.” All three of these chemovars contain abundant THC-V, with the V1 variety being especially distinguished by producing more THC-V than THC by percent weight. The V3 strain, also known as Skelator, will be the predominant strain utilized for spring cultivation due to its early finishing characteristics and its higher THC-V content, although the V1 and V2 varieties are also planned for Sugarmade’s cultivation effort.
Sugarmade plans to utilize the THC-V rich biomass in a series of products it plans to introduce to the licensed California marketplace. The first of these will be THC-V-rich smokeable flower and THC-V-rich gummy candies. In the future, Sugarmade plans to also produce distillate and isolate products based on its cultivated biomass.
Chan continued, “The THC-V smoking and edibles consumption experience is very different compared to traditional cannabis. Where legacy cannabis strains often produce a sedating effect, consumption of THC-V rich products produces a pleasant and uplifting effect. It’s a remarkable experience and we believe consumers will gravitate to it.”
In addition to seeking to supply the mainstream cannabis marketplace with THC-V products, Sugarmade also plans to seek pharmaceutical and nutraceutical partners for supply agreements as many of these companies are already stating their intentions to conduct trials or to produce products containing rare cannabinoids.
The cultivated THC-V cannabinoids from the GenCann Chemovars differ significantly from the current generation of THC-V products presently available in the marketplace, most of which are converted via a chemical process from hemp-based isolates. This generation of products is also very expensive, often priced in the $50 per gram range, and is typically not tested by certified laboratories. Additionally, the cannabinoids produced by the GenCann Chemovars differ from planned offerings by other companies that utilize genetically modified organisms, such as bacteria or yeast, to create cannabinoids outside of the cannabis plant varieties. All of the cannabinoids to be generated via the GenCann Chemovars and Sugarmade’s cultivation will be produced from real cannabis plants that have been specifically bred for this purpose and grown in an outdoor setting.
Sugarmade and GenCann believe outdoor cultivation of THC-V-rich strains will yield higher desirable cannabinoid content due to optimal ultraviolet light levels inherent in natural sunlight.
About THC-V
THC is found in the form of Tetrahydrocannabinolic acid (THCA) that is converted to THC during drying or under high heat. Similarly, THC-V in live plants is in the form of tetrahydrocannabivarin carboxylic acid (THCVA). THC and THC-V both bind to the cannabinoid receptors 1 (CB1) and 2 (CB2) although the exact effects of binding are not fully understood. Binding of CB1 by its endogenous ligands, anandamide or 2-arachidonoylglycerol, stimulates food intake (Silvestri, C., Di Marzo, V. 17 Cell Metabolism 475-490 (2013)). THC acts as an agonist of CB1 and stimulates appetite. THC-V has been shown to be a mild antagonist of CB1 and lessens sensations of hunger (Pertwee, R G. 153 British Journal of Pharmacology 199-215 (2008)). The ability of THC-V to act as an antagonist of CB1 has led to investigation of using THC-V to treat metabolic syndrome and obesity (Riedel, G., et al., 156 British Journal of Pharmacology 1154-1166 (2009)). Selection of a variety producing increased amounts of THC-V allows optimized isolation of THC-V which may be used in the treatment of metabolic syndrome.
About Sugarmade
Sugarmade, Inc. (OTC Pink: SGMD) is a product and branding marketing company investing in operations and technologies with disruptive potential. Our Brand portfolio includes CarryOutsupplies.com, SugarRush™, NUG Avenue, Lemon Glow and Budcars. Sugarmade is also the first licensee of the unique and patented Gen
sgmd$$$$_Sugarmade Signs Binding LOI to Enter Rare Cannabinoid Market via License Agreement for Patented THC-V Rich Chemovars
Sugarmade, Inc.
Mon, January 24, 2022, 8:30 AM
NEW YORK, Jan. 24, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – Sugarmade, Inc. (OTC Pink: SGMD) ("Sugarmade", "SGMD" or the "Company") an emerging leader in the licensed cannabis sector, is pleased to announce the signing of a binding Letter of Intent (the “LOI”) with GenCann, Inc. (“GenCann”), the exclusive licensor for a set of cannabis chemovars particularly rich in the cannabinoid Tetrahydrocannabivarin (THC-V) (the “GenCann Chemovars”).
Under the terms outlined in the LOI, Sugarmade and its licensed cannabis cultivator partners will be granted a 5-year license to cultivate what the Company believes to be some of the highest THC-V-containing strains in existence. Sugarmade and GenCann plan to begin clone production immediately upon the signing of the final agreement with a cultivation program beginning in Lake County, California, this spring.
“While THC-V is sometimes referred to as a ‘rare cannabinoid,’ we believe the term no longer applies relative to our planned cultivation effort using GenCann’s Chemovars,” commented Jimmy Chan, CEO of Sugarmade. “The test results from certified California laboratories of these chemovars are certainly impressive, with THC-V yields in flower of up to 8%. We think the GenCann Chemovars are a game-changer in the cannabinoid space. Sugarmade plans to make a substantial commitment to bring products based on THC-V to the California market and perhaps to other states in the future. Stay tuned for our upcoming product plan announcements.”
The GenCann Chemovars are covered by multiple issued U.S. patents, including patent numbers PP33212 for the plant called “V1,” patent number PP33211 for the plant called “V2” and patent number PP33210 for the plant called “V3.” All three of these chemovars contain abundant THC-V, with the V1 variety being especially distinguished by producing more THC-V than THC by percent weight. The V3 strain, also known as Skelator, will be the predominant strain utilized for spring cultivation due to its early finishing characteristics and its higher THC-V content, although the V1 and V2 varieties are also planned for Sugarmade’s cultivation effort.
Sugarmade plans to utilize the THC-V rich biomass in a series of products it plans to introduce to the licensed California marketplace. The first of these will be THC-V-rich smokeable flower and THC-V-rich gummy candies. In the future, Sugarmade plans to also produce distillate and isolate products based on its cultivated biomass.
Chan continued, “The THC-V smoking and edibles consumption experience is very different compared to traditional cannabis. Where legacy cannabis strains often produce a sedating effect, consumption of THC-V rich products produces a pleasant and uplifting effect. It’s a remarkable experience and we believe consumers will gravitate to it.”
In addition to seeking to supply the mainstream cannabis marketplace with THC-V products, Sugarmade also plans to seek pharmaceutical and nutraceutical partners for supply agreements as many of these companies are already stating their intentions to conduct trials or to produce products containing rare cannabinoids.
The cultivated THC-V cannabinoids from the GenCann Chemovars differ significantly from the current generation of THC-V products presently available in the marketplace, most of which are converted via a chemical process from hemp-based isolates. This generation of products is also very expensive, often priced in the $50 per gram range, and is typically not tested by certified laboratories. Additionally, the cannabinoids produced by the GenCann Chemovars differ from planned offerings by other companies that utilize genetically modified organisms, such as bacteria or yeast, to create cannabinoids outside of the cannabis plant varieties. All of the cannabinoids to be generated via the GenCann Chemovars and Sugarmade’s cultivation will be produced from real cannabis plants that have been specifically bred for this purpose and grown in an outdoor setting.
Sugarmade and GenCann believe outdoor cultivation of THC-V-rich strains will yield higher desirable cannabinoid content due to optimal ultraviolet light levels inherent in natural sunlight.
About THC-V
THC is found in the form of Tetrahydrocannabinolic acid (THCA) that is converted to THC during drying or under high heat. Similarly, THC-V in live plants is in the form of tetrahydrocannabivarin carboxylic acid (THCVA). THC and THC-V both bind to the cannabinoid receptors 1 (CB1) and 2 (CB2) although the exact effects of binding are not fully understood. Binding of CB1 by its endogenous ligands, anandamide or 2-arachidonoylglycerol, stimulates food intake (Silvestri, C., Di Marzo, V. 17 Cell Metabolism 475-490 (2013)). THC acts as an agonist of CB1 and stimulates appetite. THC-V has been shown to be a mild antagonist of CB1 and lessens sensations of hunger (Pertwee, R G. 153 British Journal of Pharmacology 199-215 (2008)). The ability of THC-V to act as an antagonist of CB1 has led to investigation of using THC-V to treat metabolic syndrome and obesity (Riedel, G., et al., 156 British Journal of Pharmacology 1154-1166 (2009)). Selection of a variety producing increased amounts of THC-V allows optimized isolation of THC-V which may be used in the treatment of metabolic syndrome.
About Sugarmade
Sugarmade, Inc. (OTC Pink: SGMD) is a product and branding marketing company investing in operations and technologies with disruptive potential. Our Brand portfolio includes CarryOutsupplies.com, SugarRush™, NUG Avenue, Lemon Glow and Budcars. Sugarmade is also the first licensee of the unique and patented Gen
sgmd-Sugarmade Signs Binding LOI to Enter Rare Cannabinoid Market via License Agreement for Patented THC-V Rich Chemovars
Sugarmade, Inc.
Mon, January 24, 2022, 8:30 AM
NEW YORK, Jan. 24, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – Sugarmade, Inc. (OTC Pink: SGMD) ("Sugarmade", "SGMD" or the "Company") an emerging leader in the licensed cannabis sector, is pleased to announce the signing of a binding Letter of Intent (the “LOI”) with GenCann, Inc. (“GenCann”), the exclusive licensor for a set of cannabis chemovars particularly rich in the cannabinoid Tetrahydrocannabivarin (THC-V) (the “GenCann Chemovars”).
Under the terms outlined in the LOI, Sugarmade and its licensed cannabis cultivator partners will be granted a 5-year license to cultivate what the Company believes to be some of the highest THC-V-containing strains in existence. Sugarmade and GenCann plan to begin clone production immediately upon the signing of the final agreement with a cultivation program beginning in Lake County, California, this spring.
“While THC-V is sometimes referred to as a ‘rare cannabinoid,’ we believe the term no longer applies relative to our planned cultivation effort using GenCann’s Chemovars,” commented Jimmy Chan, CEO of Sugarmade. “The test results from certified California laboratories of these chemovars are certainly impressive, with THC-V yields in flower of up to 8%. We think the GenCann Chemovars are a game-changer in the cannabinoid space. Sugarmade plans to make a substantial commitment to bring products based on THC-V to the California market and perhaps to other states in the future. Stay tuned for our upcoming product plan announcements.”
The GenCann Chemovars are covered by multiple issued U.S. patents, including patent numbers PP33212 for the plant called “V1,” patent number PP33211 for the plant called “V2” and patent number PP33210 for the plant called “V3.” All three of these chemovars contain abundant THC-V, with the V1 variety being especially distinguished by producing more THC-V than THC by percent weight. The V3 strain, also known as Skelator, will be the predominant strain utilized for spring cultivation due to its early finishing characteristics and its higher THC-V content, although the V1 and V2 varieties are also planned for Sugarmade’s cultivation effort.
Sugarmade plans to utilize the THC-V rich biomass in a series of products it plans to introduce to the licensed California marketplace. The first of these will be THC-V-rich smokeable flower and THC-V-rich gummy candies. In the future, Sugarmade plans to also produce distillate and isolate products based on its cultivated biomass.
Chan continued, “The THC-V smoking and edibles consumption experience is very different compared to traditional cannabis. Where legacy cannabis strains often produce a sedating effect, consumption of THC-V rich products produces a pleasant and uplifting effect. It’s a remarkable experience and we believe consumers will gravitate to it.”
In addition to seeking to supply the mainstream cannabis marketplace with THC-V products, Sugarmade also plans to seek pharmaceutical and nutraceutical partners for supply agreements as many of these companies are already stating their intentions to conduct trials or to produce products containing rare cannabinoids.
The cultivated THC-V cannabinoids from the GenCann Chemovars differ significantly from the current generation of THC-V products presently available in the marketplace, most of which are converted via a chemical process from hemp-based isolates. This generation of products is also very expensive, often priced in the $50 per gram range, and is typically not tested by certified laboratories. Additionally, the cannabinoids produced by the GenCann Chemovars differ from planned offerings by other companies that utilize genetically modified organisms, such as bacteria or yeast, to create cannabinoids outside of the cannabis plant varieties. All of the cannabinoids to be generated via the GenCann Chemovars and Sugarmade’s cultivation will be produced from real cannabis plants that have been specifically bred for this purpose and grown in an outdoor setting.
Sugarmade and GenCann believe outdoor cultivation of THC-V-rich strains will yield higher desirable cannabinoid content due to optimal ultraviolet light levels inherent in natural sunlight.
About THC-V
THC is found in the form of Tetrahydrocannabinolic acid (THCA) that is converted to THC during drying or under high heat. Similarly, THC-V in live plants is in the form of tetrahydrocannabivarin carboxylic acid (THCVA). THC and THC-V both bind to the cannabinoid receptors 1 (CB1) and 2 (CB2) although the exact effects of binding are not fully understood. Binding of CB1 by its endogenous ligands, anandamide or 2-arachidonoylglycerol, stimulates food intake (Silvestri, C., Di Marzo, V. 17 Cell Metabolism 475-490 (2013)). THC acts as an agonist of CB1 and stimulates appetite. THC-V has been shown to be a mild antagonist of CB1 and lessens sensations of hunger (Pertwee, R G. 153 British Journal of Pharmacology 199-215 (2008)). The ability of THC-V to act as an antagonist of CB1 has led to investigation of using THC-V to treat metabolic syndrome and obesity (Riedel, G., et al., 156 British Journal of Pharmacology 1154-1166 (2009)). Selection of a variety producing increased amounts of THC-V allows optimized isolation of THC-V which may be used in the treatment of metabolic syndrome.
About Sugarmade
Sugarmade, Inc. (OTC Pink: SGMD) is a product and branding marketing company investing in operations and technologies with disruptive potential. Our Brand portfolio includes CarryOutsupplies.com, SugarRush™, NUG Avenue, Lemon Glow and Budcars. Sugarmade is also the first licensee of the unique and patented Gen
y!
NTRR
-4.00%
Tue, January 18, 2022, 7:30 AM
In this article:
NTRR
-4.00%
KATY, TX / ACCESSWIRE / January 18, 2022 / Neutra Corp. (OTC PINK:NTRR) continues plans for Phase-1 clinical trials regarding the effectiveness of two hemp-based cannabinoids (CBDa) in stopping COVID-19 infection. The tests seek to build upon an earlier Oregon State University study published in the Journal of Nature Products that showed cannabis compounds cannabidiolic acid (CBDa) and cannabigerolic acid (CBGa) prevented the coronavirus from penetrating human cells. Bloomberg recently reported on the study and its results.
"We remain committed to these hemp-based CBD phase-1 clinical trials," said Neutra CEO Sydney Jim. "The earlier study showed great promise. I know it will take time to get started and but this is part of our plans for 2022. We are hopeful that our trials will show that hemp-based cannabinoid compounds to be a safe way to help to protect people from the coronavirus and SARS-CoV-2 that continues to plague the world after two years."
Neutra announced last September that its VIVIS subsidiary had signed a letter of intent with Mercury Clinical Research to pursue such trials. The main uses for CBD have been helping with inflammation, anxiety and sleep. The trials could also investigate additional hemp-based compound uses for anti-inflammation, anti-insomnia, appetite suppressant and stimulant (CBG vs. CBN), recovery, pain-management, anti-anxiety, and other health related diagnosis
CBDa and CBGa can be taken orally. Based on the published Oregon State study, VIVIS has developed a new gummy product containing the compounds. The company expects the gummy to help in the battle against COVID. CBDa can be used to combat inflammation, pain and nausea. CBGa may also be effective in fighting metabolic disorders and cardiovascular disease.
About Neutra Corp.
Neutra Corp. (OTC PINK:NTRR) is an early-stage research and development company with a focus on bringing modern healthy living solutions to a multibillion-dollar market. Cutting-edge technologies within the nutraceuticals, food, and drug, and environmental purification sectors are creating a new kind of world culture-one where in which consumers are dema
looks like where ahead of the game here by a wk
y!
NTRR
-4.00%
Tue, January 18, 2022, 7:30 AM
In this article:
NTRR
-4.00%
KATY, TX / ACCESSWIRE / January 18, 2022 / Neutra Corp. (OTC PINK:NTRR) continues plans for Phase-1 clinical trials regarding the effectiveness of two hemp-based cannabinoids (CBDa) in stopping COVID-19 infection. The tests seek to build upon an earlier Oregon State University study published in the Journal of Nature Products that showed cannabis compounds cannabidiolic acid (CBDa) and cannabigerolic acid (CBGa) prevented the coronavirus from penetrating human cells. Bloomberg recently reported on the study and its results.
"We remain committed to these hemp-based CBD phase-1 clinical trials," said Neutra CEO Sydney Jim. "The earlier study showed great promise. I know it will take time to get started and but this is part of our plans for 2022. We are hopeful that our trials will show that hemp-based cannabinoid compounds to be a safe way to help to protect people from the coronavirus and SARS-CoV-2 that continues to plague the world after two years."
Neutra announced last September that its VIVIS subsidiary had signed a letter of intent with Mercury Clinical Research to pursue such trials. The main uses for CBD have been helping with inflammation, anxiety and sleep. The trials could also investigate additional hemp-based compound uses for anti-inflammation, anti-insomnia, appetite suppressant and stimulant (CBG vs. CBN), recovery, pain-management, anti-anxiety, and other health related diagnosis
CBDa and CBGa can be taken orally. Based on the published Oregon State study, VIVIS has developed a new gummy product containing the compounds. The company expects the gummy to help in the battle against COVID. CBDa can be used to combat inflammation, pain and nausea. CBGa may also be effective in fighting metabolic disorders and cardiovascular disease.
About Neutra Corp.
Neutra Corp. (OTC PINK:NTRR) is an early-stage research and development company with a focus on bringing modern healthy living solutions to a multibillion-dollar market. Cutting-edge technologies within the nutraceuticals, food, and drug, and environmental purification sectors are creating a new kind of world culture-one where in which consumers are dema
jimmy is going to prove u wrong,he told me so